Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Stock Code: 300957 Stock Name: Botanee Announcement No.: 2024-012
Yunnan Botanee Bio-Technology Group Co., Ltd.
Quarterly Report 2024 Q1
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate and
complete without false record, misleading statement or major omission.
Notices:
1. The Board of Directors and Board of Supervisors, as well as directors, supervisors and senior management of the Company
guarantee that the present quarterly report is true, accurate and complete without false record, misleading statement or major
omission, and undertake the joint and several legal liabilities.
2. Botanee’s legal representative Mr. Guo Zhenyu, CFO Mr. Wang Long, and Head of Accounting Department Mr. Liu Zhaofeng
hereby declare that the financial statements herein are true, accurate, and complete.
3. Whether Q1 report has been audited
□Yes No
1
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
I. Key Financial Data
(i) Major Accounting Data and Financial Indicators
Whether the Company needs to retrospectively adjust or restate the accounting data for the previous years
□Yes No
Change in This
Same Period of the Reporting Year
This Reporting
Previous Year over the Same
Period
Period of the
Previous Year (%)
Operating revenue (CNY) 1,096,940,645.49 863,307,083.80 27.06%
Net profit attributable to shareholders of the listed company
176,845,231.47 158,265,044.32 11.74%
(CNY)
Net profit attributable to shareholders of the listed company
154,346,690.47 126,577,596.71 21.94%
after deducting non-recurring profit or loss (CNY)
Net cash flows from operating activities (CNY) -157,714,269.99 -196,770,597.63 19.85%
Basic earnings per share (CNY/share) 0.42 0.37 13.51%
Diluted earnings per share (CNY/share) 0.42 0.37 13.51%
Weighted average return on net assets 3.07% 2.81% Increase 0.26pcts
Change in the End of
End of This End of the This Reporting Year
Reporting Period Previous Year over the End of the
Previous Year (%)
Total assets 7,060,400,018.28 7,506,930,342.79 -5.95%
Net assets attributable to shareholders of the listed 5,958,766,569.72 5,860,994,371.02 1.67%
company (CNY)
Whether the Company’s share capital has changed and affected the amount of shareholders’ equity due to new issues, additional
issues, rights issues, stock ownership incentive exercise, buybacks and other reasons from the end of the reporting period to the
disclosure date of the quarterly report
Yes No
This Reporting Period
Dividends for Preferred Shares That Have Been Paid (CNY)
Interest Paid on Perpetual Bonds (CNY)
Fully Diluted Dividends per Share Based on Latest Share
Capital (CNY/Share)
0.4175
(ii) Item and Amount of Non-recurring Profit and Loss
Applicable □ N/A
Unit: CNY
Item Amount for Description
2
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
This Reporting
Period
Profit or loss from disposal of non-current assets Profit or loss from disposal of non-
3,159,516.70
(including the offset part of provisions for impairment of assets) current assets
Government subsidies included in the current profit or loss (excluding
those closely related to the normal business of the Company, granted
Government subsidies and incentives
under the national policies and continuously enjoyed according to 6,081,973.96
included in “other income” item
certain standards with lasting impacts on the Company’s profit and
loss)
Except for the effective hedging activities related to the Company’s
Profit or loss from changes in fair value
ordinary activities, profit or loss arising from changes in fair value of
of cash management projects handled
financial assets and financial liabilities held by non-financial 12,444,776.07
by third parties with the Company’s
enterprises, and profit or loss arising from from disposal of financial
authorization
assets and financial liabilities
Income from mature investment in cash
Profits and losses on the assets by entrusting others to invest or management projects handled by third
10,720,698.39
manage parties with the Company’s
authorization
Other non-operating income and expenses other than the above -5,751,517.93 Mainly the donations for public welfare
Less: Effect on income tax 4,012,913.49
Effect on minority interests (after-tax) 143,992.70
Total 22,498,541.00 --
Other profit or loss conforming to the definition of non-recurring profit or loss
□ Applicable N/A
There is no other profit or loss conforming to the definition of non-recurring profit or loss
Explanation on defining the non-recurring profits and losses set out in the Explanatory Announcement No. 1 on Information
Disclosure for Companies Offering Securities to the Public - Non-Recurring Profit or Loss as recurring profits and losses
□ Applicable N/A
There is no non-recurring profits and losses set out in the Explanatory Announcement No. 1 on Information Disclosure for
Companies Offering Securities to the Public - Non-Recurring Profit or Loss as recurring profits and losses
(iii) Changes in Major Accounting Data and Financial Indicators and Reasons
Applicable □ N/A
1. Changes in the Items of Consolidated Balance Sheet at the End of the Reporting Period and Reasons
Unit: CNY
Balance at the End Balance at the Proportion on
Item of the Reporting Beginning of the Change Increase/
Period Year Decrease
Cash at bank and on hand 1,343,444,241.12 2,091,459,861.58 -748,015,620.46 -35.77%
Financial assets held for trading 1,610,799,112.41 1,238,356,707.34 372,442,405.07 30.08%
3
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Notes receivable 24,502,124.46 -24,502,124.46 -100.00%
Accounts receivable financing 137,531,755.44 156,659,263.78 -19,127,508.34 -12.21%
Prepayments 142,355,751.12 69,279,116.38 73,076,634.74 105.48%
Other receivables 32,793,188.57 29,748,433.09 3,044,755.48 10.24%
Other current assets 394,885,442.12 446,396,252.76 -51,510,810.64 -11.54%
Projects under construction 17,926,811.70 40,220,147.41 -22,293,335.71 -55.43%
Right-of-use assets 138,735,183.22 100,712,614.93 38,022,568.29 37.75%
Deferred income tax assets 105,499,904.49 93,131,250.45 12,368,654.04 13.28%
Short-term loans 169,222,593.55 103,816,588.60 65,406,004.95 63.00%
Notes payable 29,733,807.46 67,562,710.23 -37,828,902.77 -55.99%
Accounts receivable 112,449,307.13 334,370,604.40 -221,921,297.27 -66.37%
Employee salary payable 68,560,161.83 106,452,763.55 -37,892,601.72 -35.60%
Tax payable 72,434,971.41 132,117,765.46 -59,682,794.05 -45.17%
Other payables 176,049,497.02 449,282,195.16 -273,232,698.14 -60.82%
Other current liabilities 8,595,035.17 5,455,465.77 3,139,569.40 57.55%
Long-term loans 857,142.85 4,700,000.00 -3,842,857.15 -81.76%
Lease liabilities and non-current
137,147,012.77 105,385,826.61 31,761,186.16 30.14%
liabilities due within one year
Treasury shares 200,212,194.96 109,838,205.82 90,373,989.14 82.28%
Reasons for Changes:
(1) The balance of monetary resources at the end of the reporting period stood at CNY1,343,444,200, a decrease of CNY748,015,600
or about 35.77% compared with the beginning of the year. For changes in major cash flow of the Company’s monetary resources
during the reporting period, please refer to 3. Changes in Consolidated Statements of Cash Flow from the Beginning of the Year to
the End of the Reporting Period and Reasons of this Report.
(2) The total balance of trading financial assets at the end of the reporting period stood at CNY1,610,799,100, an increase of
CNY372,442,400 or about 30.08% compared with the beginning of the year, mainly due to the increased immature investment
balance of cash management projects (managed by third parties with the Company’s authorization and measured at fair value) with
available funds raised and its own funds within the quota authorized by the general meeting of shareholders at the end of the
reporting period.
(3) There was no balance of notes receivable at the end of the reporting period, a significant decrease compared with the beginning of
the year, mainly due to the mature commercial acceptance held by the Company during the reporting period and the full recovery of
relevant receivables.
(4) The balance of receivables financing at the end of the reporting period stood at CNY137,531,800, a decrease of CNY19,127,500
or about 12.21% compared with the beginning of the year, mainly due to the Company’s bill planning through various means such as
acceptance at maturity, advance discount or endorsement transfer according to dynamic capital demands, and the decreased balance
of available bank acceptance at the end of the reporting period.
(5) The balance of prepayments at the end of the reporting period stood at CNY142,355,800, an increase of CNY73,076,600
4
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
compared with the beginning of the year or about 105.48%. The prepayments were mainly top-ups for promoting online stores on
large B2C e-commerce platforms for marketing plans such as live streaming and advertising and production plans on the supply
chain in the second quarter of 2024, marketing fees charged by marketing service providers and some core raw materials and
materials purchased by OEM service providers. At the end of the reporting period, the Company had a big balance of prepayments,
which was consistent with the Company’s production, marketing and sales models and cycles. The Company’s major expenses,
major suppliers and the proportion of prepayments to total assets at the end of the first quarter of 2024 did not change significantly
compared with the end of the same period of the previous year. At the end of the reporting period, there were no associated parties of
the Company among those who the Company had to make prepayments to. There was no fund misappropriation or illegal provision
of financial assistance by an associated party. At the end of the reporting period, the Company’s prepayment ratio within one year
was about 99.01%. These prepayments are expected to be written off within the next 12 months.
(6) The balance of other receivables at the end of the reporting period stood at CNY32,793,200, an increase of CNY3,044,800 or
about 10.24% compared with the beginning of the year, mainly due to the increased rental deposit for logistics stores paid by the
Company during the reporting period.
(7) The balance of other liquid assets at the end of the reporting period stood at CNY394,885,400, a decrease of CNY51,510,800 or
about 11.54% compared with the beginning of the year, mainly due to the decrease in the Company’s outstanding VAT credits and
VAT reductions to be verified and deducted at the end of the reporting period.
(8) The balance of projects under construction at the end of the reporting period stood at CNY17,926,800, a decrease of
CNY22,293,300 or about 55.43% compared with the beginning of the year, mainly due to the transfer of the freeze-dried mask
production line project of the new base of the Company’s central factory to fixed assets after passing the check for acceptance during
the reporting period. This project only uses the Company’s own funds and will increase the Company’s self-production capacity of
patch masks after being put into production.
(9) The balance of the right-of-use assets at the end of the reporting period stood at CNY138,735,200, an increase of CNY38,022,600
or about 37.75% compared with the beginning of the year, mainly due to the increase in the Company’s current lease contracts for
business premises during the reporting period. These business premises rented by the Company were mainly for production, R&D,
storage and office purposes at the end of the reporting period.
(10) The balance of deferred income tax assets at the end of the reporting period stood at CNY105,499,900, an increase of
CNY12,368,700 or about 13.28% compared with the beginning of the year, mainly due to the increased deductible temporary
differences in the Company’s lease liabilities, equity incentive expenses and deductible losses at the end of the reporting period.
(11) The balance of short-term loans at the end of the reporting period stood at CNY169,222,600, an increase of CNY65,406,000 or
about 63.00% compared with the beginning of the year, mainly due to a big increase in short-term financial loans for liquid capital
issued by commercial banks during the reporting period.
(12) The balance of notes payable at the end of the reporting period stood at CNY29,733,800, a decrease of CNY37,828,900 or about
55.99% compared with the beginning of the year, mainly due to the decrease in the remaining immature bank acceptance payable at
the end of the reporting period. At the end of the reporting period, the Company had no notes payable due or unaccepted.
(13) The balance of accounts payable at the end of the reporting period stood at CNY112,449,300, a decrease of CNY221,921,300 or
about 66.37% compared with the beginning of the year, mainly due to the Company’s payments for production materials and
5
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
productive services as scheduled. During the reporting period, the Company had no overdue payments due to suppliers.
(14) The balance of salary payable to employees at the end of the reporting period stood at CNY68,560,200, a decrease of
CNY37,892,600 or about 35.60% compared with the beginning of the year, mainly due to the Company’s payment for the year-end
one-time bonus to employees for the year 2023 during the reporting period.
(15) The balance of taxes payable at the end of the reporting period stood at CNY72,435,000, a decrease of CNY59,682,800 or about
45.17% compared with the beginning of the year, mainly due to the Company’s payment for various taxes payable preliminarily
calculated by the Company at the beginning of the reporting period.
(16) The balance of other payables at the end of the reporting period stood at CNY176,049,500, a decrease of CNY273,232,700 or
about 60.82% compared with the beginning of the year, mainly due to the Company’s payment for the marketing fees charged by
large B2C e-commerce platforms and other marketing service providers accrued in the fourth quarter of 2023, and for engineering
equipment for the new base of the central factory and other engineering projects as scheduled, and shorter cycles of other balances
payable. At the end of the reporting period, the Company’s other balances payable were small, consistent with the Company’s
marketing and sales models and cycles. The Company’s major expenses, major suppliers and the proportion of other payables to total
assets at the end of the first quarter of 2024 did not change significantly compared with the end of the same period of the previous
year. At the end of the reporting period, there were no associated parties of the Company among those who the Company had to
make prepayments to. There was no fund misappropriation or illegal provision of financial assistance by an associated party.
(17) The balance of other liquid liabilities at the end of the reporting period stood at CNY8,595,000, an increase of CNY3,139,600 or
about 57.55% compared with the beginning of the year, mainly due to the increased balance of returns payable accrued by the
Company at the end of the reporting period.
(18) The balance of long-term loans at the end of the reporting period stood at CNY857,100, a decrease of CNY3,842,900 compared
with the beginning of the year. This big decrease was mainly due to the Company’s repayment of the principal of long-term financial
loans from commercial banks at the end of the reporting period according to dynamic capital demands.
(19) The total balance of lease liabilities and non-liquid liabilities due within one year at the end of the reporting period stood at
CNY137,147,000, an increase of CNY31,761,200 or about 30.14% compared with the beginning of the year, mainly due to the
increase in the Company’s current lease contracts for business premises at the end of the reporting period. These business premises
rented by the Company were mainly for production, R&D, storage and office purposes at the end of the reporting period. The total
balance of lease liabilities and non-liquid liabilities due within one year at the end of the reporting period was basically consistent
with the changes in the balance of right-of-use assets at the end of the reporting period.
(20) The balance of treasury shares at the end of the reporting period stood at CNY200,212,200, an increase of CNY90,374,000 or
about 82.28% compared with the beginning of the year, mainly due to the increase in the Company’s ordinary shares repurchased
with its own funds through call auction in accordance with the resolution of the Board of Directors during the reporting period. For
details, please refer to the Announcement by Yunnan Botanee Bio-Technology Group Co., Ltd. on the Progress of Share Repurchase
(2024-009) disclosed on cninfo’s website (http://www.cninfo.com.cn).。
6
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
2. Changes in the Items of Consolidated Income Statement from the Beginning of the Year to the End of
the Reporting Period and Reasons
Unit: CNY
Amount Incurred in Proportion on
Item Current Amount the Same Period of Change Increase/
the Previous Year Decrease
Operating revenue 1,096,940,645.49 863,307,083.80 233,633,561.69 27.06%
Operating costs 306,201,911.22 206,280,038.13 99,921,873.09 48.44%
Tax and additional tax 8,603,141.17 7,790,149.34 812,991.83 10.44%
Marketing expenses 512,649,843.99 410,938,284.12 101,711,559.87 24.75%
Administration expenses 75,651,161.21 66,631,543.70 9,019,617.51 13.54%
Other incomes 7,985,377.36 4,825,935.94 3,159,441.42 65.47%
Investment income 10,575,655.89 5,688,720.31 4,886,935.58 85.91%
Income from changes in fair value 12,444,776.07 31,451,953.37 -19,007,177.30 -60.43%
Losses from credit impairment
-752,582.03 -2,738,672.93 1,986,090.90 72.52%
(losses are marked with “-”)
Losses from asset impairment(losses
1,521,923.22 -4,313,168.81 5,835,092.03 135.29%
are marked with “-”)
Asset disposal income 3,159,516.70 718,876.65 2,440,640.05 339.51%
Income tax 22,507,593.29 18,954,031.76 3,553,561.53 18.75%
Reasons for Changes:
(1) The Company’s operating revenue from the beginning of the year to the end of the reporting period stood at CNY1,096,940,600,
an increase of CNY233,633,600 or about 27.06% compared with the same period of the previous year, mainly due to the further
improvement of the Company’s products and brand awareness from the beginning of the year to the end of the reporting period,
which led to bigger sales scale and higher sales revenue. These figures included the sales revenue of Za and PURE&MILD, which
the Company successfully acquired on October 31, 2023. Taking into consideration only the brands included during the last reporting
period, the Company’s operating revenue stood at about CNY959,395,100 from the beginning of the year to the end of the reporting
period, an increase of about 11.13%.
(2) The Company’s operating costs from the beginning of the year to the end of the reporting period stood at CNY306,201,900, an
increase of CNY99,921,900 or about 48.44% compared with the same period of the previous year, mainly due to the increased
operating costs as the Company’s sales scale and sales revenue rose. These figures included the marketing costs of Za and
PURE&MILD, which the Company successfully acquired on October 31, 2023. Taking into consideration only the brands included
during the last reporting period, the Company’s operating costs stood at about CNY247,494,900 from the beginning of the year to the
end of the reporting period, an increase of about 19.98%. The gross profit margin on sales was about 74.20%. The growth of the
Company’s operating costs basically matched the growth of the sales scale, and the production costs were basically stable. From the
beginning of the year to the end of the reporting period, the growth rate of operating costs was slightly higher than that of operating
revenue, mainly due to the dynamic adjustments of the Company’s promotion policies and product portfolios according to the market.
(3) The Company’s tax and additional tax from the beginning of the year to the end of the reporting period stood at CNY8,603,100,
an increase of CNY813,000 or about 10.44% compared with the same period of the previous year, mainly due to the increased tax
and additional tax as the Company’s sales scale and sales revenue rose. The growth rate of the Company’s tax and additional tax
from the beginning of the year to the end of the reporting period was lower than that of the sales revenue, mainly due to the decreased
7
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
input VAT plus tax credits and the decreased taxable sales revenue for consumption tax during the reporting period.
(4) The Company’s marketing expenses from the beginning of the year to the end of the reporting period stood at CNY512,649,800,
an increase of CNY101,711,600 or about 24.75% compared with the same period of the previous year, mainly due to the
continuously increased investment in brand image promotion and communication, human resources and storage as the Company’s
sales scale and sales revenue rose. The growth of the Company’s marketing expenses basically matched that of the sales scale.
(5) The Company’s administration expenses from the beginning of the year to the end of the reporting period stood at
CNY75,651,200, an increase of CNY9,019,600 or about 13.54% compared with the same period of the previous year, mainly due to
the increased salary of managerial staff, equity incentive costs and other administrative expenses as the Company scaled up. The
growth rate of the Company’s administration expenses from the beginning of the year to the end of the reporting period was lower
than that of the sales scale, mainly due to the effective cost reduction and efficiency improvement measures for administrative
functions and back-stage management expenses implemented by the Company during the reporting period.
(6) The Company’s other incomes from the beginning of the year to the end of the reporting period stood at CNY7,985,400, an
increase of CNY3,159,400 or about 65.47% compared with the same period of the previous year, mainly due to the increased tax
credits of input VAT and the increased revenue-related government subsidies for the Company compared with the same period of
the previous year from the beginning of the year to the end of the reporting period.
(7) The Company’s investment income from the beginning of the year to the end of the reporting period stood at CNY10,575,700,
an increase of CNY4,886,900 or about 85.91% compared with the same period of the previous year. This big increase was mainly
due to the increased maturity yield generated by the Company’s cash management projects (managed by third parties with the
Company’s authorization and measured at fair value) from the beginning of the year to the end of the reporting period.
(8) The Company’s net income from changes in fair value from the beginning of the year to the end of the reporting period stood
at CNY12,444,800, a decrease of CNY19,007,200 or about 60.43% compared with the same period of the previous year, mainly
due to the decreased fair value fluctuations of the cash management projects (managed by third parties with the Company’s
authorization and measured at fair value) compared with the same period of the previous year during the reporting period.
(9) The Company’s net losses from credit impairment from the beginning of the year to the end of the reporting period stood at
CNY752,600, a decrease of CNY1,986,100 compared with the same period of the previous year. This big decrease was mainly due
to the decreased provision for receivables impairment during the reporting period. During the reporting period, there were no
changes in the Company’s accounting policies and accounting estimates for the provision for receivables impairment.
(10) The Company’s net income from asset impairment from the beginning of the year to the end of the reporting period stood at
CNY1,521,900, mainly due to the net write-back of the Company’s provision for inventory impairment. During the reporting
period, there were no changes in the Company’s accounting policies and accounting estimates for the provision for inventory
impairment.
(11) The Company’s asset disposal income from the beginning of the year to the end of the reporting period stood at
CNY3,159,500, an increase of CNY2,440,600 compared with the same period of the previous year. This big year-on-year increase
was mainly due to the early termination of lease contracts and the cancellation of right-of-use assets during the reporting period.
8
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
(12) The Company’s income tax from the beginning of the year to the end of the reporting period stood at CNY22,507,600, an
increase of CNY3,553,600 or about 18.75% compared with the same period of the previous year, mainly due to the increased
corporate income tax as the sales scale and total profits increased.
3. Changes in the Items of Consolidated Statement of Cash Flow from the Beginning of the Year to the
End of the Reporting Period and Reasons
Unit: CNY
Amount Incurred in the Proportion on Increase/
Item Current Amount Same Period of the Change
Decrease
Previous Year
Cash inflow from
1,289,100,731.71 956,511,167.50 332,589,564.21 34.77%
business operations
Cash outflow to business
1,446,815,001.70 1,153,281,765.13 293,533,236.57 25.45%
operations
Cash inflow from
681,304,135.99 1,062,386,090.04 -381,081,954.05 -35.87%
investment activities
Cash outflow to
1,112,435,766.79 1,679,824,366.87 -567,388,600.08 -33.78%
investment activities
Cash inflow from
69,222,593.55 69,222,593.55
financing activities
Cash outflow to
225,881,999.09 21,609,005.20 204,272,993.89 945.31%
financing activities
Reasons for Changes:
(1) The Company’s cash inflow from business operations from the beginning of the year to the end of the reporting period stood at
CNY1,289,100,700, an increase of CNY332,589,600 or about 34.77% compared with the same period of the previous year, mainly
due to the increased cash inflow brought by the rapid growth of the Company’s sales scale and sales revenue. From the beginning
of the year to the end of the reporting period, the growth of cash inflow from business operations basically matched that of the
sales scale.
(2) The Company’s cash outflow to business operations from the beginning of the year to the end of the reporting period stood at
CNY1,446,815,000, an increase of CNY293,533,200 or about 25.45% compared with the same period of the previous year, mainly
due to the increase in other operating expenses incurred by brand image promotion and communication, human resources and e-
commerce platforms. From the beginning of the year to the end of the reporting period, the growth of cash outflow to business
operations basically matched that of the sales scale.
(3) The Company’s cash inflow from investment activities from the beginning of the year to the end of the reporting period stood
at CNY681,304,100, a decrease of CNY381,082,000 or about 35.87% compared with the same period of the previous year, mainly
due to the immaturity of major cash management projects managed by third parties with the Company’s authorization at the end of
the reporting period.
(4) The Company’s cash outflow to investment activities from the beginning of the year to the end of the reporting period stood at
CNY1,112,435,800, a decrease of CNY567,388,600 or about 33.78% compared with the same period of the previous year, mainly
due to the immaturity of major cash management projects managed by third parties with the Company’s authorization and
9
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
decreased investment in cash management projects with available funds raised and its own funds within the smaller quota
authorized by the general meeting of shareholders from the beginning of the year to the end of the reporting period.
(5) The Company’s cash inflow from financing activities from the beginning of the year to the end of the reporting period stood at
CNY69,222,600, mainly due to the cash of short-term financial loans received from commercial banks for liquid capital during the
reporting period.
(6) The Company’s cash outflow to financing activities from the beginning of the year to the end of the reporting period stood at
CNY225,882,000, an increase of CNY204,273,000 compared with the same period of the previous year, mainly because the
Company repurchased its ordinary shares with its own funds through call auction according to the resolution of the Board of
Directors and repaid the principal and interest of long-term and short-term financial loans to commercial banks according to
dynamic capital demands.
II. Shareholder Information
(i) Total Number of Ordinary Shareholders and the Number of Preferred Shareholders Whose Voting
Rights Have Been Restored and Shareholding of Top 10 Shareholders
Unit: Share
Total number of preferred
Total number of ordinary share shareholders (if any)
shareholder s as of the end of the 34,356 resuming voting rights at
reporting period the end of the reporting
period
Shareholdings of top 10 shareholders (excluding shares lent through conversions)
Number of Pledged, marked or
Shareholdi shares frozen shares
ng Number of subject to
Shareholder Name Nature
proportion shares held trading Status of
Quantity
(%) restriction shares
held
Domestic non-
Kunming Nuona Technology Co., Not
state-owned 46.08% 195,212,611.00
Ltd. Applicable
corporate
Tianjin Sequoia Juye Equity Domestic non-
Not
Investment Partnership (Limited state-owned 14.58% 61,763,257.00
Applicable
Partnership) corporate
Domestic non-
Xiamen Zhenli Consulting Co., Not
state-owned 6.54% 27,685,934.00
Ltd. Applicable
corporate
Overseas
Hong Kong Securities Clearing Not
legal 3.28% 13,886,556.00
Company Limited Applicable
person
Domestic non-
Yunnan Haqisheng Enterprise Not
state-owned 2.60% 10,993,678.00
Management Co., Ltd. Applicable
corporate
Xiamen Chonglou Yunshui Domestic non-
Not
Investment Partnership (Limited state-owned 1.30% 5,526,929.00
Applicable
Partnership) corporate
10
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Overseas
Not
Kuwait Investment Authority legal 1.25% 5,285,437.00
Applicable
person
National Social Security Fund Not
Miscellaneous 0.66% 2,816,813.00
102 Portfolio Applicable
Industrial and Commercial Bank
of China Limited - Efund GEM Not
Miscellaneous 0.57% 2,433,281.00
Exchange-traded Open Index Applicable
Securities Investment Fund
National Social Security Fund Not
Miscellaneous 0.47% 1,992,075.00
504 Portfolio Applicable
Shareholdings of top ten shareholders without trading limited condition
Number of shares Types of shares
not subject to
Shareholder trading restriction Types of
Quantity
as at the end of shares
reporting period
CNY common
Kunming Nuona Technology Co., Ltd. 195,212,611.00 195,212,611.00
shares
Tianjin Sequoia Juye Equity Investment Partnership CNY common
61,763,257.00 61,763,257.00
(Limited Partnership) shares
CNY common
Xiamen Zhenli Consulting Co., Ltd. 27,685,934.00 27,685,934.00
shares
CNY common
Hong Kong Securities Clearing Company Limited 13,886,556.00 13,886,556.00
shares
CNY common
Yunnan Haqisheng Enterprise Management Co., Ltd. 10,993,678.00 10,993,678.00
shares
Xiamen Chonglou Yunshui Investment Partnership CNY common
5,526,929.00 5,526,929.00
(Limited Partnership) shares
CNY common
Kuwait Investment Authority 5,285,437.00 5,285,437.00
shares
CNY common
National Social Security Fund 102 Portfolio 2,816,813.00 2,816,813.00
shares
Industrial and Commercial Bank of China Limited -
CNY common
Efund GEM Exchange-traded Open Index Securities 2,433,281.00 2,433,281.00
shares
Investment Fund
CNY common
National Social Security Fund 504 Portfolio 1,992,075.00 1,992,075.00
shares
Kunming Nuona Technology Co., Ltd. and Yunnan Haqisheng Enterprise
Management Co., Ltd. are both controlled by Guo Zhenyu and KEVIN
Description on the related relationship or concerted
GUO (father and son), the actual controllers of the Company. Except
action among the above shareholders
this, the Company does not know whether other shareholders have an
association or a concerted action relationship.
Description of top 10 shareholders participating in
Not applicable.
securities margin trading (if any)
Note: As of March 31, 2024, the number of shares held under the unlimited sale condition in the buyback special securities
account of Yunnan Botanee Bio-Technology Group Co., Ltd. was 2,994,618 shares, accounting for approximately 0.71% of the
Company’s issued CNY ordinary shares at the end of the reporting period.
Securities financing and share lending of shareholders holding more than 5%, top 10 shareholders and top 10 shareholders of
unlimited tradable shares
□Applicable Not Applicable
11
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Changes over the previous period because top 10 shareholders and the top 10 shareholders holding shares not subject to trading
restriction lend/return securities financing
□Applicable Not Applicable
(ii) Total number of preferred shareholders and top 10 preferred shareholders of the Company
□Applicable Not Applicable
(III) Changes in Restricted Shares
Applicable Not Applicable
Unit: Share
Termination in Increase in
Number of
Number of the current the current
period period Restricted Reasons for
restricted trading Release
Shareholder Name shares as at
shares as at the Number of Number of restriction date of
beginning of the end of
restricted restricted restriction
the period the period
shares shares
Shares
Kunming Nuona Technology Co., before March 25,
195,212,611.00 195,212,611.00
Ltd. initial public 2024
offerings
Shares
Yunnan Haqisheng Enterprise before March 25,
10,993,678.00 10,993,678.00
Management Co., Ltd. initial public 2024
offerings
Total 206,206,289.00 206,206,289.00
Note: For details, please refer to the Indicative Announcement on the Circulation of Some Issued Shares of Yunnan Botanee Bio-
Technology Group Co., Ltd. (2024-008) before IPO on cninfo’s website (http://www.cninfo.com.cn).
III. Other Important Matters
□Applicable Not Applicable
IV. Quarterly Financial Statement
(i) Financial Statement
1. Consolidated Balance Sheet
Prepared by: Yunnan Botanee Bio-Technology Group Co., Ltd.
12
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
March 31, 2024
Unit: CNY
Balance at the End of the Balance at the Beginning of
Item
Reporting Period the Reporting Period
Current assets:
Cash at bank and on hand 1,343,444,241.12 2,091,459,861.58
Settlement reserves
Loans to banks and other financial institutions
Financial assets held for trading 1,610,799,112.41 1,238,356,707.34
Derivative financial assets
Notes receivable 24,502,124.46
Accounts receivable 512,174,991.94 561,761,929.57
Receivables financing 137,531,755.44 156,659,263.78
Advances to suppliers 142,355,751.12 69,279,116.38
Premiums receivable
Reinsurance premium receivable
Reinsurance contract reserves receivable
Other accounts receivable 32,793,188.57 29,748,433.09
Including: interest receivable
Dividends receivable
Financial assets purchased under agreement store sell
Inventories 830,566,558.90 904,413,283.67
Including: data resources
Contract assets
Held-for-sale assets
Current portion of non-current assets
Other current assets 394,885,442.12 446,396,252.76
Total current assets 5,004,551,041.62 5,522,576,972.63
Non-current assets:
Disbursement of loans and advances to customers
Debt investment
Other debt investment
Long-term receivables
Long-term equity investment 218,370,108.65 212,015,151.15
Investment in other equity instruments
Other non-current financial assets 91,449,823.00 86,449,823.00
Investment real estates 8,702,323.26 9,021,481.56
Fixed assets 686,030,584.71 667,204,436.83
Projects under construction 17,926,811.70 40,220,147.41
Productive biological assets
Oil and gas assets
13
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Right-of-use assets 138,735,183.22 100,712,614.93
Intangible assets 199,099,505.63 193,108,638.64
Including: data resources
Development expenditures
Including: data resources
Goodwill 413,740,760.61 413,740,760.61
Long-term deferred expenses 93,306,043.71 93,317,644.84
Deferred income tax assets 105,499,904.49 93,131,250.45
Other non-current assets 82,987,927.68 75,431,420.74
Total non-current assets 2,055,848,976.66 1,984,353,370.16
Total assets 7,060,400,018.28 7,506,930,342.79
Current liabilities:
Short-term borrowings 169,222,593.55 103,816,588.60
Borrowings from the central bank
Placements from banks and other financial institutions
Financial liabilities held for trading
Derivative financial liabilities
Notes payable 29,733,807.46 67,562,710.23
Accounts payable 112,449,307.13 334,370,604.40
Advances from customers
Contract liabilities 50,698,653.60 50,053,638.68
Financial assets sold under agreements to repurchase
Customer bank deposits and due to banks and other
financial institutions
Customer brokerage deposits
Securities underwriting brokerage deposits
Employee compensation payable 68,560,161.83 106,452,763.55
Taxes payable 72,434,971.41 132,117,765.46
Other payables 176,049,497.02 449,282,195.16
Including: interests payable 69,661.77
Dividends payable 4,305.04
Handling charges and commission payable
Reinsurance premium payable
Held-for-sale liabilities
Non-current liabilities due within one year 55,891,140.02 42,102,294.00
Other current liabilities 8,595,035.17 5,455,465.77
Total current liabilities 743,635,167.19 1,291,214,025.85
Non-current liabilities:
Insurance contract reserves
Long-term borrowings 857,142.85 4,700,000.00
14
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Bonds payable
Including: Preferred shares
Perpetual bonds
Lease liabilities 81,255,872.75 63,283,532.61
Long-term payables 8,600,000.00 8,600,000.00
Long-term employee benefits payable
Estimated liabilities
Deferred income 77,500,127.96 82,862,738.40
Deferred tax liabilities 39,370,161.08 40,452,457.50
Other non-current liabilities
Total non-current liabilities 207,583,304.64 199,898,728.51
Total liabilities 951,218,471.83 1,491,112,754.36
Owners' equity:
Share capital 423,600,000.00 423,600,000.00
Other equity instruments
Including: Preferred shares
Perpetual bonds
Capital reserves 2,859,970,626.92 2,846,004,685.04
Less: treasury shares 200,212,194.96 109,838,205.82
Other comprehensive incomes -1,101,763.25 47,153.49
Special reserves
Surplus reserve 211,081,299.10 211,081,299.10
General risk provision
Undistributed profit 2,665,428,601.91 2,490,099,439.21
Total owners' equity attributable to the parent company 5,958,766,569.72 5,860,994,371.02
Minority interest 150,414,976.73 154,823,217.41
Total owners' equity 6,109,181,546.45 6,015,817,588.43
Total liabilities and owners' equity 7,060,400,018.28 7,506,930,342.79
Legal representative: Guo Zhenyu CFO: Wang Long Head of Accounting Department: Liu
Zhaofeng
15
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
2. Consolidated Income Statement
Unit: CNY
Amount of the Reporting Amount of Precious
Item
Period Reporting Period
I. Total operating revenue 1,096,940,645.49 863,307,083.80
Including: Operating revenue 1,096,940,645.49 863,307,083.80
Interest income
Earned premiums
Handling charges and commission income
II. Total operating cost 931,179,210.70 718,760,135.76
Including: operating costs 306,201,911.22 206,280,038.13
Interest expenses
Handling charges and commission expenses
Surrender value
Net payments for insurance claims
Net provision for insurance contract reserves
Policy dividend expenses
Reinsurance expenses
Taxes and surcharges 8,603,141.17 7,790,149.34
Selling expenses 512,649,843.99 410,938,284.12
Management expenses 75,651,161.21 66,631,543.70
R&D expenses 32,646,832.96 33,955,217.71
Financial expenses -4,573,679.85 -6,835,097.24
Including: interest expenses 2,770,460.67 1,098,960.38
Interest income -7,594,888.61 -8,274,640.69
Add: other incomes 7,985,377.36 4,825,935.94
Investment income (loss to be listed with “-”) 10,575,655.89 5,688,720.31
Including: income from investment in associates and
joint -145,042.50
ventures
Revenue from derecognition of financial
assets at 5,058,786.22
amortized cost
Exchange earnings (losses to be listed with “-”)
Net exposure hedging income (loss to be listed with “-”)
Profit arising from changes in fair value (loss expressed 12,444,776.07 31,451,953.37
with "- ")
Credit impairment losses (losses to be listed with “-”) -752,582.03 -2,738,672.93
Asset impairment loss (loss to be listed with "-") 1,521,923.22 -4,313,168.81
Incomes of assets disposal (losses to be listed with “-”) 3,159,516.70 718,876.65
III. Operating profit (loss to be listed with "-") 200,696,102.00 180,180,592.57
Add: non-operating revenue 268,588.39 400,768.55
16
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Less: Non-operating expenses 6,020,106.32 6,612,043.18
IV. Total profit (total loss to be listed with "-") 194,944,584.07 173,969,317.94
Less: income tax expenses 22,507,593.29 18,954,031.76
V. Net profit (net loss to be listed with "-") 172,436,990.78 155,015,286.18
(I) Classified by going concern
1. Net profit from continuing operations (net loss to be 172,436,990.78 155,015,286.18
listed with “-”)
2. Net profit from discontinued operations (net loss to
be listed with "-")
(II) Classified by attribution of ownership
1.Net profit attributable to the parent company's 176,845,231.47 158,265,044.32
shareholders
2. Non-controlling interests -4,408,240.69 -3,249,758.14
VI. Net of tax of other comprehensive income -1,148,916.74
Other net after-tax comprehensive income attributable to the -1,195,875.08
owners of the parent company
(I) Other comprehensive income that cannot be
reclassified through profit or loss
1. Changes arising from re-measurement of the defined
benefit
plan
2. Other comprehensive incomes that cannot be
reclassified into profit or loss under the equity method
3. Changes in fair value of other equity instrument
investments
4. Changes in fair value of the Company’s credit risk
5. Others
(II) Other comprehensive income to be reclassified into -1,195,875.08
profit or loss
1. Other comprehensive income that can be
reclassified into profit or loss under the equity method
2. Changes in fair value of other creditor's rights
investments
3. Amount of financial assets reclassified
into other comprehensive incomes
4. Provision for impairment of credit in other debt
investments
5. Reserves for cash flow hedge
6. Translation difference arising from foreign currency -1,195,875.08
financial statements
7. Others
Other net after-tax comprehensive income attributable to 46,958.34
minority shareholders
VII. Total comprehensive income 171,288,074.04 155,015,286.18
Total comprehensive income attributable to the owners of the 175,649,356.39 158,265,044.32
parent company
Total comprehensive income attributable to minority -4,361,282.35 -3,249,758.14
shareholders
VIII. Earnings per share
(I) Basic earnings per share 0.42 0.37
(II) Diluted earnings per share 0.42 0.37
In case of business combinations under common control in current period, the net profit realized by the combined party before
combination is CNY 0.00 and the net profit realized by the combined party in previous period is CNY 0.00.
17
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Legal representative: Guo Zhenyu CFO: Wang Long Head of
Accounting
Department: Liu
Zhaofeng
18
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
3. Consolidated Cash Flow Statement
Unit: CNY
Amount of the Reporting Amount of Precious
Item
Period Reporting Period
I. Cash flows from operating activities:
Cash received from sales of goods or rendering of services 1,275,917,110.75 944,703,091.31
Net increase in deposits from customers and placements
from banks and other financial institutions
Net increase in borrowings from the central bank
Net increase in placements from other financial institutions
Cash received for receiving premium of original insurance
contract
Net cash received from reinsurance business
Net increase in deposits of the insured and investment
Cash received from interest, handling charges and commission
Net increase in placements from banks and other
financial institutions
Net increase in capital for repurchase
Net cash received from securities trading agency services
Taxes and surcharges refunds 1,585,654.76
Other cash received relating to operating activities 13,183,620.96 10,222,421.43
Subtotal of cash inflows from operating activities 1,289,100,731.71 956,511,167.50
Cash paid for goods and services 379,949,715.47 336,605,023.22
Net increase in loans and advances to customers
Net increase in deposits in the central bank and other
financial institutions
Cash paid for claim settlements on original insurance contract
Net increase in placements from banks and other
financial institutions
Cash paid for interest, handling charges and commission
Cash paid for policy dividends
Cash paid to and for employees 235,214,505.18 202,534,843.45
Payments of taxes and surcharges 127,754,843.63 116,290,752.97
Other cash paid relating to operating activities 703,895,937.42 497,851,145.49
Subtotal of cash outflows from operating activities 1,446,815,001.70 1,153,281,765.13
Net cash flow from operating activities -157,714,269.99 -196,770,597.63
II. Cash flows from investing activities:
Cash received from the return of investment 670,000,000.00 1,049,617,111.10
Cash received from investment incomes 11,304,135.99 10,059,178.94
Net cash received from the disposal of fixed assets, 2,709,800.00
intangible assets, and other long-term assets
19
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Net cash received from the disposal of subsidiaries
and other business entities
Other cash received relating to investing activities
Subtotal of cash inflows from investing activities 681,304,135.99 1,062,386,090.04
Cash paid to acquire fixed assets, intangible assets and 70,935,766.79 37,406,207.05
other long- term assets
Cash paid to acquired investments 1,041,500,000.00 1,641,416,055.23
Net increase in pledge loans
Net cash paid for acquisition of subsidiaries and other 1,002,104.59
business entities
Other cash paid relating to investment activities
Subtotal of cash outflows from investing activities 1,112,435,766.79 1,679,824,366.87
Net cash flows from investing activities -431,131,630.80 -617,438,276.83
III. Cash flows from financing activities:
Cash received from absorbing investments
Including: Cash received by subsidiaries from minority
shareholders'investments
Cash received from borrowings 69,222,593.55
Cash received relating to other financing activities
Subtotal of cash inflows from financing activities 69,222,593.55
Cash paid for repayment of debts 107,642,857.15
Cash paid for distribution of dividends, profits or interest 2,491,963.96 1,520,824.84
repayment
Including: cash payments for dividends or profit to 1,217,455.37 1,520,824.84
minority shareholders of subsidiaries
Other cash paid relating to financing activities 115,747,177.98 20,088,180.36
Subtotal of cash outflows from financing activities 225,881,999.09 21,609,005.20
Net cash flows from financing activities -156,659,405.54 -21,609,005.20
IV. Effects from the change of exchange rate on cash -942,902.91 -394.71
and cash equivalents
V. Net increase in cash and cash equivalents -746,448,209.24 -835,818,274.37
Add: Opening balance of cash and cash equivalents 2,073,881,743.78 2,440,692,701.42
VI. Closing balance of cash and cash equivalents 1,327,433,534.54 1,604,874,427.05
Legal representative: Guo Zhenyu CFO: Wang Long Head of Accounting Department: Liu
Zhaofeng
(II) Information about Adjusting Related Items in Financial Statements for the Year at
the Beginning of the Year According to New Accounting Standards Since 2024
Applicable N/A
For details, please refer to the Announcement by Yunnan Botanee Bio-Technology Group Co., Ltd. on Changes in Accounting
Policies on cninfo’s website (http://www.cninfo.com.cn)
20
Quarterly Report 2024 Q1 of Yunnan Botanee Bio-Technology Group Co., Ltd.
(iii) Audit Report
Whether the Q1 report has been audited
□Yes No
The Q1 report of the Company has not been audited
Board of Directors of Yunnan Botanee Bio-Technology Group Co., Ltd.
April 24, 2024
21
